Project Title

Principal InvestigatorPosition
Cancer
Nanoscale Formulations of the Anticancer Agent DocetaxelDr. Pieter CullisCDRD Scientific Director and Professor, Dept. of Biochemistry & Molecular Biology, UBC
Inhibition of Autophagy using siRNADr. Sharon GorskiBC Genome Sciences Centre and Associate Professor, Biochemistry & Molecular Biology, SFU
Chemical Inhibitors of Autophagy as New Cancer Therapy AgentsDr. Michel RobergeProfessor, Dept. of Biochemistry & Molecular Biology, UBC
Ceratamines, Microtubule-Stabilizing Antitumour AgentsDr. Raymond AndersenProfessor, Dept. of Earth & Ocean Sciences, UBC
MicroRNAs as Therapeutic Agents in Acute Myeloid LeukemiaDr. Keith HumphriesProfessor, Pathology & Lab Medicine, BC Cancer Agency, UBC
Intravesicular Paclitaxel for Bladder CancerDr. Helen BurtCDRD Division Head and Professor, Faculty of Pharmaceutical Sciences, UBC
Identification of Tdp1 Inhibitors for Treatment of SCAN1 and CancerDr. Cornelius BoerkoelAssociate Professor, Medical Genetics, Faculty of Medicine
Development of Irinophore C for the treatment of colorectal cancerDr. Dawn WaterhouseBritish Columbia Cancer Agency
Neurological Disease
Therapeutic Strategies for Huntington’s DiseaseDr. Michael HaydenDirector/Professor, Centre for Molecular Medicine & Therapeutics, UBC
Metabolic Disease
An Enzyme Inhibitor for Treating Type-2 DiabetesDr. Andrew BennetProfessor, Dept. of Chemistry, SFU
α-Amylase Inhibitors for Type-2 DiabetesDr. Stephen WithersProfessor, Dept. of Chemistry, UBC
Tetrahydroxylated Bile Acids as Novel Choleretic AgentsDr. Victor LingProfessor, Department of Biochemistry and Molecular Biology, UBC, Department Head, Cancer Genetics, BC Cancer Agency
Inhibition of IAPP Accumulation as a Treatment Approach for diabetes

Dr. Bruce Verchere

Associate Professor, Dept. of Pathology and Laboratory Medicine, UBC

Dr. Paul Fraser

Professor, Dept. of Medical Biophysics, University of Toronto

Infectious Disease
Formulation of Cationic Peptides for Systemic UseDr. Robert HancockProfessor, Dept. of Microbiology & Immunology, UBC
Other
Selective EP4 Agonists for the Treatment of Inflammatory Bowel DiseasesDr. Robert YoungProfessor, Dept. of Chemistry, SFU
Selective Peptide Inhibitors of TGF-β1 Activation For The Treatment of Idiopathic Pulmonary FibrosisDr. Nasreen KhalilClinical Professor of Medicine, The Lung Centre, Gordon and Leslie Diamond Health Care Centre
Inhibition of Granzyme B for Treatment of Abdominal Aortic AneurysmsDr. David GranvilleAssistant Professor, Dept. of Pathology and Laboratory Medicine, UBC